{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:15:22Z","timestamp":1788156922572,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To address the need for long\u2010term efficacy and patient\u2010reported outcomes (PROs) data for patients with atopic dermatitis (AD) treated with baricitinib 2\u00a0mg, a study was conducted to evaluate the efficacy of baricitinib 2\u00a0mg in adult patients with moderate\u2010to\u2010severe AD. Data presented here provided efficacy and outcomes data for patients treated for 52\u2009weeks. Patients who participated in the originating study, BREEZE\u2010AD5 (NCT03435081), and met additional eligibility criteria could enroll in the multicenter, open\u2010label, Phase 3, long\u2010term extension study BREEZE\u2010AD6 (NCT03559270). Patients received baricitinib 2\u00a0mg for the duration of BREEZE\u2010AD6. In BREEZE\u2010AD6, the proportion of patients who achieved a 75% improvement in the Eczema Area and Severity Index (EASI75) and validated Investigator Global Assessment for AD (vIGA\u2010AD\u2122) of 0 (clear) or 1 (almost clear) were assessed through 52\u2009weeks, in addition to several PROs. At week 52, the proportion of patients treated with baricitinib 2\u00a0mg daily achieving EASI75 was 48.6% (70\/144), and 31.3% (45\/144) of patients achieved a vIGA\u2010AD score of 0 or 1 (clear or almost clear). Improvements in PROs such as SCORing Atopic Dermatitis (SCORAD, itch and sleep) scores, Dermatology Life Quality Index (DLQI) total score, and DLQI \u22645 response were observed, and these responses were sustained through 52\u2009weeks. Long\u2010term efficacy of baricitinib in patients with AD was demonstrated by both clinician and patient\u2010reported outcome measures.<\/jats:p>","DOI":"10.1111\/dth.15954","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T22:44:26Z","timestamp":1666392266000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baricitinib 2\u00a0mg for the treatment of atopic dermatitis in\n                    <scp>North America<\/scp>\n                    : Long\u2010term efficacy and patient\u2010reported outcomes"],"prefix":"10.1155","volume":"35","author":[{"given":"Eric","family":"Simpson","sequence":"first","affiliation":[{"name":"Department of Dermatology Oregon Health and Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[{"name":"Division of Allergy\u2010Immunology, Department of Pediatrics National Jewish Health and University of Colorado School of Medicine  Denver Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelma C.","family":"Chiesa Fuxench","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Pennsylvania Perelman School of Medicine  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Feely","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"},{"name":"Department of Dermatology Mount Sinai Health System  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Sun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun\u2010Fei","family":"Chen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robinette","family":"Angle","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology George Washington University School of Medicine and Health Sciences  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2010.22.2.125"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-011-0003-5"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12154"},{"key":"e_1_2_11_5_1","unstructured":"AbbeA Falissard B Gadkari A Wei W Arnold R Eckert L.Atopic dermatitis from the patient's perspective: insights from text\u2010mining analysis of a cross\u2010sectional study in US adults. Poster presented at: 75th Annual Meeting of American Academy of Dermatology; March 3\u20137 2017; Orlando FL.https:\/\/www.aad.org\/eposters\/view\/Abstract.aspx?id=4781"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.06.010"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1195733"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.019"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.028"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1273"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2017.38.4005"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18657"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13685"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.036"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.07.010"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17278"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370226"},{"key":"e_1_2_11_23_1","article-title":"Sleep disturbances in atopic dermatitis in US adults","author":"Silverberg JI","year":"2021","journal-title":"Dermatitis"},{"key":"e_1_2_11_24_1","first-page":"2057","article-title":"Improvement in sleep and itch and enhanced quality of life in adult patients with moderate\u2010to\u2010severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy","volume":"1","author":"Lio PA","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dth.15954","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.15954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:36:49Z","timestamp":1788154609000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.15954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/dth.15954"],"URL":"https:\/\/doi.org\/10.1111\/dth.15954","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"2022-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15954"}}